logo
logo

Leo Lens Pharma Achieves Two Significant Milestones – FDA IND Submission and Seed Round Fundraising Success

Nov 12, 2020•over 4 years ago

Round Type

seed

San Diego

Description

Today, Leo Lens Pharma, an emerging San Diego-based pharmaceutical company focused on helping protect sight, announces the achievement of two significant milestones. The first is the filing in the United States of the Food and Drug Administration's (FDA’s) Investigational New Drug (IND) application for its lead asset, a proprietary drug-eluting, comfort-enhancing contact lens to treat patients suffering from primary open-angle glaucoma or ocular hypertension. The second is the securement of a lead investor, the venture arm of a leading global ophthalmic pharmaceutical company, and initial funding in its Seed round fundraising efforts.

Company Information

Company

Leo Lens Pharma

Location

San Diego, California, United States

About

Leo Lens Pharma (Leo Lens) is an emerging San Diego-based pharmaceutical company focused on helping protect sight by developing and commercializing a proprietary continuous ocular drug delivery portfolio. The Company is currently advancing its lead asset, a unique and complete glaucoma treatment, to the clinic while continuing to build out its product portfolio for dry eye, allergy, and other anterior segment conditions. Using its proprietary MediPrint™ process, Leo Lens will initially commercialize a drug-eluting, comfort-enhancing contact lens to treat millions of glaucoma patients worldwide. While eye drops have been around for over 40 years and remain the standard of care for over 90% of patients, they have only around a 50% compliance rate. This leads millions to suffer from disease progression and thousands to suffer from preventable blindness. There is a large unmet need for a better non-invasive treatment option in this $4B U.S. market. Leo Lens’ patented MediPrint™ process offers a unique value proposition for patients, practitioners, strategic partners, and payers.